Literature DB >> 16400431

[Non-functioning pituitary adenomas: clinical features and immunohistochemistry].

Jane Eyre Alves Ferreira1, Paulo Andrade de Mello, Albino Verçosa de Magalhães, Carlos Henrique Aguiar Botelho, Luciana Ansaneli Naves, Vania Nosé, Fernando Schmitt.   

Abstract

UNLABELLED: Clinically non-functioning pituitary adenomas do not produce clinical signs of hormonal hypersecretion. Therefore, signs and symptoms will depend on the mass effect of these adenomas over the central nervous system. Their etiopathogeny is complex and their development is probably influenced by several factors, such as hypothalamic hormones (GHRH), growth factors (FGF), proliferation factors (PCNA, and KI-67), protein P53 and the proto-oncogene c-erb-B2.
OBJECTIVE: 1) Determining the clinical features of a population of 117 patients treated for clinically non-functioning pituitary adenoma (age, sex, tumor size, number of surgical procedures, development of hormonal deficiency and hyperprolactinemia). 2) Identifying, after the patients had been clinically characterized, those with clinically non-functioning adenomas with positive immunohistochemistry for hypophyseal hormones (PRL, LH, FSH, GH, TSH and ACTH). 3) Determining if the immunohistochemistry of this population was positive for the cellular proliferation factor Ki-67, protein P53 and protein C-erb-B2 and establishing a correlation with tumor size and tumor invasiveness. This will help in the evaluation of the prognostic value of these proliferation factors. 4) Confronting the results of immunohistochemistry using a standard block with the results of immunohistochemistry using a tissue micro-array.
METHOD: Study of the clinical features of 117 patients with clinically non-functioning pituitary adenoma (age, sex, tumor size, number of surgical procedures, development of hormonal deficiency and hyperprolactinemia). Immunohistochemical study (H&E) of 39 patients for hypophyseal hormones, protein P53, protein C-erb-B2, Ki-67 to establish their correlation to tumor growth. The next step was a tissue micro-array of the 39 previously studied cases, using immunohistochemistry for hypophyseal hormones, protein P 53, protein C-erb-B2, Ki-67 to establish their correlation to tumor growth.
RESULTS: There was no statistically significant difference between males and females with regards to age, tumor size and number of surgical procedures (p=0.279, p=813, p=139 respectively). There is a statistically significant correlation between the size of the tumor, the number of surgical procedures and hormonal deficiency (p=0.032, p=0.223 respectively). There was no statistically significant correlation between a positive immunohistochemistry for protein P53, protein C-erb-B2, Ki-67 and tumor size (r=0.182, p=0.396; r=-0.181, p=0.397; r=0.272, p=0.199, respectively). The tissue micro-array also did not demonstrate a correlation between positive immunohistochemistry for Ki-67 and C-erb-B2 and tumor size, but it showed a statistically significant correlation between a positive immunohistochemistry for p53 and tumor size (r=-0.696; p=001).
CONCLUSION: The biological behavior of the clinically non-functioning adenoma is similar for both sexes. The larger the tumor the greater the number of surgical procedures needed. Hormonal deficiency also becomes more significant as the size of the tumor increases. This paper suggests that a positive immunohistochemistry for p53 is negatively correlated to tumor size, thus demonstrating that it has a predictor value. However, a positive immunohistochemistry for Ki-67 and protein C-erb-B2 does not seem to be a prognostic factor for clinically non-functioning pituitary adenomas, as is the case with other neoplasias.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16400431     DOI: 10.1590/s0004-282x2005000600029

Source DB:  PubMed          Journal:  Arq Neuropsiquiatr        ISSN: 0004-282X            Impact factor:   1.420


  7 in total

1.  Vasculogenic Mimicry in Clinically Non-functioning Pituitary Adenomas: a Histologic Study.

Authors:  Joseph Di Michele; Fabio Rotondo; Kalman Kovacs; Luis V Syro; George M Yousef; Michael D Cusimano; Antonio Di Ieva
Journal:  Pathol Oncol Res       Date:  2017-01-13       Impact factor: 3.201

Review 2.  Expression and function of ErbB receptors and ligands in the pituitary.

Authors:  Odelia Cooper; George Vlotides; Hidenori Fukuoka; Mark I Greene; Shlomo Melmed
Journal:  Endocr Relat Cancer       Date:  2011-10-27       Impact factor: 5.678

3.  Clival invasion on multi-detector CT in 390 pituitary macroadenomas: correlation with sex, subtype and rates of operative complication and recurrence.

Authors:  X Chen; J Dai; L Ai; X Ru; J Wang; S Li; G S Young
Journal:  AJNR Am J Neuroradiol       Date:  2011-03-24       Impact factor: 3.825

Review 4.  Prognostic Factors for Recurrence in Pituitary Adenomas: Recent Progress and Future Directions.

Authors:  Liang Lu; Xueyan Wan; Yu Xu; Juan Chen; Kai Shu; Ting Lei
Journal:  Diagnostics (Basel)       Date:  2022-04-13

5.  The impact of immunohistochemical markers of Ki-67 and p53 on the long-term outcome of growth hormone-secreting pituitary adenomas: A cohort study.

Authors:  Maysam Alimohamadi; Vahid Ownagh; Leila Mahouzi; Afshin Ostovar; Kazem Abbassioun; Abbas Amirjmshidi
Journal:  Asian J Neurosurg       Date:  2014 Jul-Sep

6.  Prognostic Value of Invasion, Markers of Proliferation, and Classification of Giant Pituitary Tumors, in a Georeferred Cohort in Brazil of 50 Patients, with a Long-Term Postoperative Follow-Up.

Authors:  Juliano Coelho de Oliveira Zakir; Luiz Augusto Casulari; José Wilson Corrêa Rosa; João Willy Corrêa Rosa; Paulo Andrade de Mello; Albino Verçosa de Magalhães; Luciana Ansaneli Naves
Journal:  Int J Endocrinol       Date:  2016-08-18       Impact factor: 3.257

7.  A Nomogram for Preoperatively Predicting the Ki-67 Index of a Pituitary Tumor: A Retrospective Cohort Study.

Authors:  Xiangming Cai; Junhao Zhu; Jin Yang; Chao Tang; Feng Yuan; Zixiang Cong; Chiyuan Ma
Journal:  Front Oncol       Date:  2021-05-31       Impact factor: 6.244

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.